NFKB1 and non-small cell lung carcinoma: These results indicated that rapamycin could dramatically inhibit the Escherichia-Shigella- and Enterobacteriaceae-derived LPS-induced NSCLC cell proliferation by suppressing the mTOR-NF-κB axis.